{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}],"title":"Complete Hematologic Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"18"}]}],"title":"Stable Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"40"}],"units":"Participants"}],"description":"patients will be assessed for hematologic response (the response of the clonal plasma cell disease). If the plasma cell disease persists, then they will receive 6 cycles of adjuvant therapy with bortezomib and dexamethasone; patients with peripheral neuropathy will receive dexamethasone alone because of the risk of neuropathy associated with bortezomib. Symptomatic organ involvement with amyloid as defined below. Patients must have symptomatic involvement of no more than 2 of the following 4 visceral organ-systems: kidneys, liver/GI, peripheral/autonomic nervous system, and heart.","groups":[{"description":"All patients treated with Melphalan with Stem Cell Transplant and Adjuvant Bortezomib and Dexamethasone for Recently Diagnosed Untreated Patients with Systemic Light-Chain (AL) Amyloidosis","id":"OG000","title":"All Patients"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"2-3 months post transplant","title":"Hematologic and Organ Response","type":"PRIMARY","unitOfMeasure":"participants"}